Chugai Pharmabody Research
Adrian Ho is a Principal Investigator and Senior Principal Scientist at Chugai Pharmabody Research since February 2014, where involvement includes leading projects in the Pharmacology Unit. Prior to this role, Adrian Ho worked at A-STAR from July 2011 to January 2014 as a Principal Scientist and Research Fellow, focusing on immune modulation by vaccine adjuvants, therapeutic strategies for inflammasome-mediated diseases, and innate inflammatory mechanisms related to gout. Earlier experience includes serving as a Research Assistant at the National University of Singapore from July 2006 to August 2007. Adrian Ho holds a PhD in Immunology and a Bachelor of Science in Life Sciences from the National University of Singapore, completed in 2011 and 2006, respectively.
This person is not in any offices
Chugai Pharmabody Research
1 followers
In the global medical field, there are many diseases in which there are no drug or current drugs are insufficient to address the medical needs of patients. Chugai Pharmabody Research (CPR) is a subsidiary company of Chugai Pharmaceutical in Japan, a member of Roche group, and is committed to address these unmet needs by specializing in the field of antibody drug discovery utilizing proprietary antibody engineering technologies.